| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HTR2A |
| Uniprot No | P28223 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-471aa |
| 氨基酸序列 | MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIADMLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNPIHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSFVSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIHREPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGALLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYKSSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HTR2A重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*Crystal Structure of an LSD-Bound Human Serotonin Receptor*
**作者**：Wacker, D. et al.
**摘要**：本研究通过X射线晶体学解析了人源HTR2A重组蛋白与致幻剂LSD结合的复合物结构。实验在昆虫细胞中表达并纯化HTR2A受体，揭示了LSD与受体的结合模式及激活机制，为设计靶向5-HT2A受体的药物提供了结构基础。
---
2. **文献名称**：*Pharmacological Characterization of Recombinant Human 5-HT2A Receptor Signaling in HEK293 Cells*
**作者**：Cussac, D. et al.
**摘要**：作者在HEK293细胞中重组表达HTR2A受体，系统分析了其信号转导通路(如磷脂酶C激活和钙离子动员)。研究发现不同激动剂对受体的激活效率和下游信号存在差异，为精神疾病药物开发提供了药理学依据。
---
3. **文献名称**：*Expression and Characterization of the Human 5-HT2A Receptor in Mammalian Cells*
**作者**：Almaula, N. et al.
**摘要**：该文献优化了HTR2A受体在哺乳动物细胞(CHO细胞)中的重组表达和纯化流程，并评估了其配体结合特性。研究验证了重组受体与经典拮抗剂(如酮色林)的高亲和力，确认了其在体外药物筛选中的应用潜力。
---
这些研究涵盖了HTR2A重组蛋白的结构解析、信号机制及表达优化，适用于药物开发或功能研究参考。如需更多文献或具体领域扩展，可进一步说明需求。
The HTR2A gene encodes the 5-hydroxytryptamine 2A (5-HT2A) receptor, a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. It binds serotonin (5-HT), a key neurotransmitter regulating mood, cognition, and perception. The 5-HT2A receptor signals through Gαq/11 proteins, activating phospholipase C and triggering downstream pathways involving inositol triphosphate and diacylglycerol. Its dysregulation is implicated in psychiatric disorders such as depression, schizophrenia, and anxiety, making it a major target for psychoactive drugs, including atypical antipsychotics and psychedelics like LSD and psilocybin.
Recombinant HTR2A protein is engineered using heterologous expression systems (e.g., HEK293 or insect cells) to enable structural and functional studies. These systems allow precise control over receptor production, often incorporating tags (e.g., His-tag, FLAG) for purification and detection. The recombinant form preserves key structural features, including seven transmembrane domains, extracellular ligand-binding regions, and intracellular signaling motifs. Researchers use it to study receptor-ligand interactions, signal transduction mechanisms, and allosteric modulation. It also facilitates drug discovery via high-throughput screening and supports cryo-EM studies to resolve receptor-ligand complex structures. Challenges include maintaining native post-translational modifications and membrane integration during in vitro production. Recent advances in stabilizing GPCRs with nanobodies or fusion partners have improved the utility of recombinant HTR2A in both academic and pharmaceutical research.
×
